San Diego, CA -- (SBWire) -- 06/17/2013 --An investigation on behalf of investors, who purchased shares of Dynavax Technologies Corporation (NASDAQ:DVAX) prior to February 25, 2013, is ongoing concerning Dynavax Technologies Corporatio and certain of its directors and officers whether violated Federal Securities Laws in connection certain financial statements.
Investors who purchased shares of Dynavax Technologies Corporation (NASDAQ:DVAX) have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses whether a series of statements by Dynavax Technologies regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Dynavax Technologies Corporation reported that its Total Revenue declined from $23.95 million in 2010 to $21.61 million in 2011 and that its Net Loss decreased from $57.31 million in 2010 to $48.60 million in 2011. For the first three quarters in 2012 Dynavax Technologies Corporation reported a combined nine months Total Revenue of $7.9 million with a combined nine months Net Loss of $49.40 million.
Shares of Dynavax Technologies Corporation increased from $1.83 per share in October 2011 to as high as $5.15 per share in April, respectively $4.91 per shares in October 2012.
Then on Feb. 25, 2013, Dynavax Technologies Corporation announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (“FDA” or Agency) regarding its Biologic License Application for HEPLISAV, an investigational adult hepatitis B vaccine. Among other things, the FDA specified in the complete response letter, that the indication in adults 18-70 years of age cannot be approved without further evaluation of safety in this broad age group.
Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) declined from $3.118 per share on Feb. 22, 2013 to $1.87 per share on Feb. 25, 2013.
Then on June 10, 2013 - Dynavax Technologies Corporation reported that it recently concluded a meeting with the U.S. Food and Drug Administration (“FDA”) regarding its Biologic License Application for HEPLISAV, an investigational adult hepatitis B vaccine.
Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) fell from $2.55 per share on June 6, 2013 to $1.22 per share on June 13, 2013.
Those who purchased shares of Dynavax Technologies Corporation (NASDAQ:DVAX), have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
Dynavax Technologies Corporation (NASDAQ:DVAX) Investor Alert: Investigation Announced
An investigation for investors in Dynavax Technologies Corporation (NASDAQ:DVAX) shares over potential securities laws violations by Dynavax Technologies was announced and NASDAQ:DVAX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com